Ask AI
ProCE Banner Series

Advancing Pharmacist Excellence in Solid Tumors: Essential Considerations for Expanding From IV to Subcutaneous ICIs

Expert-led educational program with insights and best practices for the management of patients with solid tumors with subcutaneous formulations for immunotherapies, including clinical pharmacy and managed care pharmacy considerations.

  ACPE-P
Who Should Attend

This activity has been designed to meet the educational needs of pharmacists and other healthcare professionals caring for patients with solid tumors.

All Events

Advancing Pharmacist Excellence in Solid Tumors: Essential Considerations for Expanding From IV to Subcutaneous ICIs

Upcoming Events

May

14

2026

1:00 PM - 2:00 PM Eastern Time (ET)

Virtual

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The activity aims to improve learners’ knowledge, confidence, and competence in educating and caring for patients with solid tumors receiving subcutaneous immune checkpoint inhibitors. 

Target Audience
This activity has been designed to meet the educational needs of pharmacists and other healthcare professionals caring for patients with solid tumors.

Learning Objectives
Upon completion of this event, participants should be able to:

  • Analyze the pharmacy practice implications of current and emerging data on subcutaneous ICIs for cancer treatment.
  • Integrate comprehensive knowledge of SC ICI therapies into pharmacy practice, focusing on preparation and administration technique, safety monitoring and management of drug-related complications, and coordination of complex regimens to optimize patient-centered care
  • Build skills to effectively counsel patients and caregivers on expectations for subcutaneous ICI therapy, including administration, efficacy, and monitoring and management of treatment-related toxicities.

Accreditation

CE Accreditation

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-26-004-L01-P has been assigned to this live application-based activity (initial release date May 14, 2026). This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.deceraclinical.com/education, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure of Conflicts of Interest
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by ProCE, LLC.

ProCE, LLC

Supporters

Supported by an educational grant from Merck Sharp & Dohme LLC.

Merck Sharp & Dohme LLC

For customer support please click here.

Mailing Address:

 

Decera Clinical
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191